Overview


According to FutureWise analysis the market for US General Anesthesia Drugs in 2023 is US$ 2.23 billion, and is expected to reach US$ 2.96 billion by 2031 at a CAGR of 3.60%.

FutureWise Market Research has instantiated a report that provides an intricate analysis of US General Anesthesia Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the US General Anesthesia Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Baxter International Inc.
  • Hikma Pharmaceuticals plc
  • Pfizer Inc.
  • Piramal Enterprises Limited AbbVie
  • Fresenius SECo. KGaA
  • Par Pharmaceutical
  • Teva Pharmaceuticals
  • Viatris/Mylan
  • Novartis AG
  • Abbott Laboratories
  • AstraZeneca plc
  • F.Hoffmann-La Roche
  • GlaxoSmithKline plc
  • Gilead Sciences, Inc.
  • Bayer AG
  • Merck & Co., Inc.
  • Sanofi
  • Heritage Pharmaceuticals Inc
  • Akorn
  • Apotex

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Route of Administration

  • Inhalational
    • Sevoflurane
    • Desflurane
    • Isoflurane
    • Nitrous Oxide
  • Intravenous
    • Propofol
    • Benzodiazepines
    • Ketamine
    • Methohexital Sodium
    • Others

By End User

  • Hospitals
  • Ambulatory Surgery Centers

By Company Type

  • Tier 1 Pharmaceutical Companies
  • Tier 2 Pharmaceutical Companies
  • Tier 3 Pharmaceutical Companies

  • Tier 1 players-established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the US General Anesthesia Drugs Market By Route of Administration, By End User, By Company Type and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— US
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   US General Anesthesia Drugs Market Variables, Trends and Scope

    •   1. Market LineProducts Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of US General Anesthesia Drugs Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   US General Anesthesia Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   US General Anesthesia Drugs Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Inhalational
         1.1. Sevoflurane
         1.2. Desflurane
         1.3. Isoflurane
         1.4. Nitrous Oxide
        2. Intravenous
         2.1. Propofol
         2.2. Benzodiazepines
         2.3. Ketamine
         2.4. Methohexital Sodium
         2.5. Others

  • 8.   US General Anesthesia Drugs Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Hospitals
        2. Ambulatory Surgery Centers

  • 9.   US General Anesthesia Drugs Market, By Company Type Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Tier 1 Pharmaceutical Companies
        2. Tier 2 Pharmaceutical Companies
        3. Tier 3 Pharmaceutical Companies

  • 10.   Market Share Analysis and Competitive Landscape

    •   1. U.S Landscape - Key Players, Revenue and Presence
        2. U.S Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. U.S Emerging Companies
        4. U.S - Market Share Analysis and Key Regional Players
        5. U.S Key Player - Growth Matrix

  • 11.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Baxter International Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Hikma Pharmaceuticals plc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Pfizer Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Piramal Enterprises Limited
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Fresenius SECo. KGaA
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Par Pharmaceutical
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Teva Pharmaceuticals
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Viatris/Mylan
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Novartis AG
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Abbott Laboratories
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. AstraZeneca plc
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
           11.4. Financial Overview
         11.5. Strategic Overview
        12. F.Hoffmann-La Roche
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. GlaxoSmithKline plc
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Gilead Sciences, Inc.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Bayer AG
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Merck & Co., Inc.
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Sanofi
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Heritage Pharmaceuticals Inc
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. Akorn
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20. Apotex
         20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         20.5. Strategic Overview

  • 12.   Pre and Post COVID-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 13.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11